Literature DB >> 23283728

Mass spectrometric distinction of in-source and in-solution pyroglutamate and succinimide in proteins: a case study on rhG-CSF.

Mukesh Kumar1, Amarnath Chatterjee, Anand P Khedkar, Mutyalasetty Kusumanchi, Laxmi Adhikary.   

Abstract

Formation of cyclic intermediates involving water or ammonia loss is a common occurrence in any reaction involving terminal amines or hydroxyl group containing species. Proteins that have both these functional groups in abundance are no exception, and presence of amino acids such as asparagine, glutamines, aspartic acids, and glutamic acids aid in formation of such intermediates. In the biopharma scenario, such intermediates lead to product- or process-related impurities that might be immunogenic. Mass spectroscopy is a powerful technique that is used to decipher the presence and physicochemical characteristics of such impurities. However, such intermediates can also form in situ during mass spectrometric analysis. We present here the detection of in-source and in-solution formation of succinimide and pyroglutamate in the protein granulocyte colony stimulating factor. We also propose an approach for quick differentiation of such in-situ species from the tangible impurities. We believe that this will not only reduce the time spent in unambiguous identification of succinimide- and/or pyroglutamate-related impurity in bio-pharmaceutics but also provide a platform for similar studies on other impurities that may form due to stabilized intermediates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283728     DOI: 10.1007/s13361-012-0531-7

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  39 in total

1.  Prediction of low-energy collision-induced dissociation spectra of peptides.

Authors:  Zhongqi Zhang
Journal:  Anal Chem       Date:  2004-07-15       Impact factor: 6.986

2.  Deamidation of -Asn-Gly- sequences during sample preparation for proteomics: Consequences for MALDI and HPLC-MALDI analysis.

Authors:  Oleg V Krokhin; Mihaela Antonovici; Werner Ens; John A Wilkins; Kenneth G Standing
Journal:  Anal Chem       Date:  2006-09-15       Impact factor: 6.986

3.  Rearrangement of terminal amino acid residues in peptides by protease-catalyzed intramolecular transpeptidation.

Authors:  Szilan Fodor; Zhongqi Zhang
Journal:  Anal Biochem       Date:  2006-07-05       Impact factor: 3.365

4.  Dehydration versus deamination of N-terminal glutamine in collision-induced dissociation of protonated peptides.

Authors:  Pedatsur Neta; Quan-Long Pu; Lisa Kilpatrick; Xiaoyu Yang; Stephen E Stein
Journal:  J Am Soc Mass Spectrom       Date:  2006-09-26       Impact factor: 3.109

Review 5.  Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods.

Authors:  J Vlasak; R Ionescu
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

Review 6.  Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor.

Authors:  A C Herman; T C Boone; H S Lu
Journal:  Pharm Biotechnol       Date:  1996

7.  Reengineering granulocyte colony-stimulating factor for enhanced stability.

Authors:  B Bishop; D C Koay; A C Sartorelli; L Regan
Journal:  J Biol Chem       Date:  2001-06-13       Impact factor: 5.157

8.  Sequence-specific predictive chromatography to assist mass spectrometric analysis of asparagine deamidation and aspartate isomerization in peptides.

Authors:  Nadezda P Sargaeva; Anton A Goloborodko; Peter B O'Connor; Eugene Moskovets; Mikhail V Gorshkov
Journal:  Electrophoresis       Date:  2011-05-09       Impact factor: 3.535

9.  Fragmentation reactions of protonated peptides containing glutamine or glutamic acid.

Authors:  Alex G Harrison
Journal:  J Mass Spectrom       Date:  2003-02       Impact factor: 1.982

10.  Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain.

Authors:  Boxu Yan; Sean Steen; David Hambly; John Valliere-Douglass; Tim Vanden Bos; Scott Smallwood; Zac Yates; Thomas Arroll; Yihong Han; Himanshu Gadgil; Ramil F Latypov; Alison Wallace; Aiching Lim; Gerd R Kleemann; Weichun Wang; Alain Balland
Journal:  J Pharm Sci       Date:  2009-10       Impact factor: 3.534

View more
  7 in total

1.  Investigation of Sequence Clipping and Structural Heterogeneity of an HIV Broadly Neutralizing Antibody by a Comprehensive LC-MS Analysis.

Authors:  Vera B Ivleva; Nicole A Schneck; Deepika Gollapudi; Frank Arnold; Jonathan W Cooper; Q Paula Lei
Journal:  J Am Soc Mass Spectrom       Date:  2018-05-07       Impact factor: 3.109

2.  Mass Spectrometry Based Mechanistic Insights into Formation of Tris Conjugates: Implications on Protein Biopharmaceutics.

Authors:  Pradeep G Kabadi; Praveen Kallamvalliillam Sankaran; Dinesh V Palanivelu; Laxmi Adhikary; Anand Khedkar; Amarnath Chatterjee
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-03       Impact factor: 3.109

3.  Gamma-carboxylation and fragmentation of osteocalcin in human serum defined by mass spectrometry.

Authors:  Douglas S Rehder; Caren M Gundberg; Sarah L Booth; Chad R Borges
Journal:  Mol Cell Proteomics       Date:  2015-04-08       Impact factor: 5.911

4.  Massive glutamine cyclization to pyroglutamic acid in human serum discovered using NMR spectroscopy.

Authors:  G A Nagana Gowda; Yashas N Gowda; Daniel Raftery
Journal:  Anal Chem       Date:  2015-03-17       Impact factor: 6.986

5.  NMR-Based Metabolomics.

Authors:  G A Nagana Gowda; Daniel Raftery
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  An artifact in LC-MS/MS measurement of glutamine and glutamic acid: in-source cyclization to pyroglutamic acid.

Authors:  Preeti Purwaha; Leslie P Silva; David H Hawke; John N Weinstein; Philip L Lorenzi
Journal:  Anal Chem       Date:  2014-06-05       Impact factor: 6.986

7.  The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES.

Authors:  Anna F Nguyen; Megan S Schill; Mike Jian; Patricia J LiWang
Journal:  Int J Mol Sci       Date:  2017-07-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.